{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:59:53Z","timestamp":1793710793241,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81747-7","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:13:24Z","timestamp":1735874004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand"],"prefix":"10.1038","volume":"15","author":[{"given":"Natthakan","family":"Chitpim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattara","family":"Leelahavarong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthamas","family":"Prawjaeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakditat","family":"Ittiphisit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varalak","family":"Srinonprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanawan","family":"Kongmalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"81747_CR1","unstructured":"IDF Diabetes Atlas. Diabetes and Kidney Disease. https:\/\/diabetesatlas.org\/atlas\/diabetes-and-kidney-disease\/ (2021)."},{"key":"81747_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-023-01202-x","volume":"15","author":"E Fenta","year":"2023","unstructured":"Fenta, E. et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol. Metab. Syndr. 15, 1. https:\/\/doi.org\/10.1186\/s13098-023-01202-x (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"81747_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260\u2013272. https:\/\/doi.org\/10.1016\/S0140-6736(13)60687-X (2013).","journal-title":"Lancet"},{"key":"81747_CR4","unstructured":"The Nephrology Society of Thailand. Clinical Practice Recommendations for Evaluation and Management of Chronic Kidney Disease in Adults 2022 (Revised edition),  https:\/\/www.nephrothai.org\/wp-content\/uploads\/2023\/03\/CKD-guideline-2565-revised-edition.pdf"},{"key":"81747_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000514550","volume":"52","author":"JS Thurlow","year":"2021","unstructured":"Thurlow, J. S. et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol. 52, 98\u2013107. https:\/\/doi.org\/10.1159\/000514550 (2021).","journal-title":"Am. J. Nephrol."},{"key":"81747_CR6","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","volume":"40","author":"V Jha","year":"2023","unstructured":"Jha, V. et al. Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD research programme. Adv. Ther. 40, 4405\u20134420. https:\/\/doi.org\/10.1007\/s12325-023-02608-9 (2023).","journal-title":"Adv. Ther."},{"key":"81747_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","volume":"22","author":"CJ Bailey","year":"2022","unstructured":"Bailey, C. J., Day, C. & Bellary, S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr. Diab. Rep. 22, 39\u201352. https:\/\/doi.org\/10.1007\/s11892-021-01442-z (2022).","journal-title":"Curr. Diab. Rep."},{"key":"81747_CR8","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ekir.2022.08.016","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau, K., Dharia, A., Alrowiyti, I., Cherney, D. Z. & I. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int. Rep. 7, 2546\u20132547. https:\/\/doi.org\/10.1016\/j.ekir.2022.08.016 (2022).","journal-title":"Kidney Int. Rep."},{"key":"81747_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816 (2020).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR10","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1056\/NEJMc2301923","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington, W. G., Baigent, C. & Haynes, R. Empagliflozin in patients with chronic kidney disease. Reply. N. Engl. J. Med. 388, 2301\u20132302. https:\/\/doi.org\/10.1056\/NEJMc2301923 (2023).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720 (2015).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR13","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925 (2017).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389 (2019).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR15","doi-asserted-by":"publisher","first-page":"120543","DOI":"10.1016\/j.lfs.2022.120543","volume":"300","author":"X Lingli","year":"2022","unstructured":"Lingli, X. & Wenfang, X. Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: a mechanism review. Life Sci. 300, 120543. https:\/\/doi.org\/10.1016\/j.lfs.2022.120543 (2022).","journal-title":"Life Sci."},{"key":"81747_CR16","unstructured":"Guideline Development Working Group. Guideline for Health Technology Assessment in Thailand Updated Edition. https:\/\/kb.hsri.or.th\/dspace\/handle\/11228\/5320?locale-attribute=en (2019)."},{"key":"81747_CR17","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf (2012)."},{"key":"81747_CR18","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1097\/MD.0000000000000475","volume":"94","author":"P Vejakama","year":"2015","unstructured":"Vejakama, P., Ingsathit, A., Attia, J. & Thakkinstian, A. Epidemiological study of chronic kidney disease progression: a large-scale population-based cohort study. Medicine (Baltim.) 94, e475. https:\/\/doi.org\/10.1097\/MD.0000000000000475 (2015).","journal-title":"Medicine (Baltim.)"},{"key":"81747_CR19","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98, S1\u2013S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019 (2020).","journal-title":"Kidney Int."},{"key":"81747_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/heapol\/czz121","volume":"35","author":"N Thammatacharee","year":"2020","unstructured":"Thammatacharee, N., Mills, A., Nitsch, D. & Lumpaopong, A. The changing patterns of access overtime to the renal replacement therapy programme in Thailand. Health Policy Plan. 35, 1\u20136. https:\/\/doi.org\/10.1093\/heapol\/czz121 (2020).","journal-title":"Health Policy Plan."},{"key":"81747_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.krcp.2014.04.001","volume":"33","author":"H Choi","year":"2014","unstructured":"Choi, H. et al. Excess mortality among patients on dialysis: comparison with the general population in Korea. Kidney Res. Clin. Pract. 33, 89\u201394. https:\/\/doi.org\/10.1016\/j.krcp.2014.04.001 (2014).","journal-title":"Kidney Res. Clin. Pract."},{"key":"81747_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"MJ Jardine","year":"2020","unstructured":"Jardine, M. J. et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J. Am. Soc. Nephrol. 31, 1128\u20131139. https:\/\/doi.org\/10.1681\/ASN.2019111168 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"81747_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","volume":"140","author":"KW Mahaffey","year":"2019","unstructured":"Mahaffey, K. W. et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation 140, 739\u2013750. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042007 (2019).","journal-title":"Circulation"},{"key":"81747_CR24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"81747_CR25","unstructured":"Bureau of trade and economic indices.  Consumer Price Index. https:\/\/www.price.moc.go.th\/price\/cpi\/index_new.asp (2023)."},{"key":"81747_CR26","unstructured":"Bank of Thailand. Foreign Exchange Rate. https:\/\/www.bot.or.th\/en\/statistics\/exchange-rate.html (2024)."},{"key":"81747_CR27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-021-02037-6","volume":"39","author":"K Vareesangthip","year":"2022","unstructured":"Vareesangthip, K., Deerochanawong, C., Thongsuk, D., Pojchaijongdee, N. & Permsuwan, U. Cost-utility analysis of dapagliflozin as an add-on to standard of care for patients with chronic kidney disease in Thailand. Adv. Ther. 39, 1279\u20131292. https:\/\/doi.org\/10.1007\/s12325-021-02037-6 (2022).","journal-title":"Adv. Ther."},{"key":"81747_CR28","doi-asserted-by":"publisher","first-page":"869535","DOI":"10.3389\/fmed.2022.869535","volume":"9","author":"A Phongphithakchai","year":"2022","unstructured":"Phongphithakchai, A. et al. Preemptive living-related kidney transplantation is a cost-saving strategy compared with post-dialysis kidney transplantation in Thailand. Front. Med. 9, 869535. https:\/\/doi.org\/10.3389\/fmed.2022.869535 (2022).","journal-title":"Front. Med."},{"key":"81747_CR29","unstructured":"Health  Intervention and Technology Assessment: HITAP Ministry of Public Health. Standard Cost Lists for Health Technology Assessment. https:\/\/costingmenu.hitap.net\/ (2010)."},{"key":"81747_CR30","unstructured":"Drug and medical supply information center & Ministry of Public Health. Average price, https:\/\/dmsic.moph.go.th\/index\/drugsearch\/3, (2023)."},{"key":"81747_CR31","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","volume":"106","author":"DS Lin","year":"2021","unstructured":"Lin, D. S., Lee, J. K. & Chen, W. J. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J. Clin. Endocrinol. Metab. 106, 2133\u20132145. https:\/\/doi.org\/10.1210\/clinem\/dgab274 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"81747_CR32","doi-asserted-by":"crossref","unstructured":"Briggs, A., Sculpher, M. & Claxton, K. Decision Modelling for Health Economic Evaluation (Oxford University Press, 2006).","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"81747_CR33","unstructured":"Drummond, M., Sculpher, M., Claxton, K., Stoddart, G. & Torrance, G. Methods for the Economic Evaluation of Health Care Programmes, 4th edn (Oxford University Press, 2015)."},{"key":"81747_CR34","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053 (2013).","journal-title":"JAMA"},{"key":"81747_CR35","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.18553\/jmcp.2020.26.12.1506","volume":"26","author":"K Folkerts","year":"2020","unstructured":"Folkerts, K. et al. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database. J. Manag. Care Spec. Pharm. 26, 1506\u20131516. https:\/\/doi.org\/10.18553\/jmcp.2020.26.12.1506 (2020).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"81747_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.18553\/jmcp.2023.29.1.80","volume":"29","author":"H Chung","year":"2023","unstructured":"Chung, H. et al. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population. J. Manag. Care Spec. Pharm. 29, 80\u201389. https:\/\/doi.org\/10.18553\/jmcp.2023.29.1.80 (2023).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"81747_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2021.09.014","volume":"79","author":"OS Reifsnider","year":"2022","unstructured":"Reifsnider, O. S. et al. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG outcome trial. Am. J. Kidney Dis. 79, 796\u2013806. https:\/\/doi.org\/10.1053\/j.ajkd.2021.09.014 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"81747_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4236\/ojneph.2023.134040","volume":"13","author":"G Saadi","year":"2023","unstructured":"Saadi, G. et al. Cost utility analysis of dapagliflozin in Egyptian patients with CKD from the payer perspective. Open J. Nephrol. 13, 40. https:\/\/doi.org\/10.4236\/ojneph.2023.134040 (2023).","journal-title":"Open J. Nephrol."},{"key":"81747_CR39","doi-asserted-by":"publisher","first-page":"e0196332","DOI":"10.1371\/journal.pone.0196332","volume":"13","author":"P Kittiskulnam","year":"2018","unstructured":"Kittiskulnam, P. et al. The magnitude of obesity and metabolic syndrome among diabetic chronic kidney disease population: a nationwide study. PLoS ONE 13, e0196332. https:\/\/doi.org\/10.1371\/journal.pone.0196332 (2018).","journal-title":"PLoS ONE"},{"key":"81747_CR40","unstructured":"World Health Organization. Global Health Observatory Data Repository: Life Tables by Country (Thailand). https:\/\/apps.who.int\/gho\/data\/?theme=main&vid=61640 (2022)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81747-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81747-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81747-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T01:03:19Z","timestamp":1735952599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81747-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["81747"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81747-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}